Pedro De Marchi

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis Paz‐Ares, Tudor–Eliade Ciuleanu, Manuel Cobo et al. · The Lancet Oncology · 2021 · 1.4K citations

Medicine, Oncology, Pharmacology +14

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

Martin Reck, Tudor–Eliade Ciuleanu, Manuel Cobo et al. · ESMO Open · 2021 · 188 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC)

Pedro De Marchi, Letícia Ferro Leal, Vinícius Duval da Silva et al. · Journal of Clinical Pathology · 2021 · 100 citations

Medicine, Oncology, Pathology +17

Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non–Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial

Edward B. Garon, Shun Lü, Yasushi Goto et al. · Journal of Clinical Oncology · 2023 · 75 citations

Medicine, Oncology, Chemotherapy +15

Determinants of COVID-19 Mortality in Patients With Cancer From a Community Oncology Practice in Brazil

Bruno Lemos Ferrari, Carlos Gil Ferreira, Márcia Menezes et al. · JCO Global Oncology · 2021 · 56 citations · Full text

Medicine, Clinical Sciences, Oncology +15